HighTower Advisors
VYGR icon

HighTower Advisors’s Voyager Therapeutics VYGR Stock Holding History

HighTower Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17,426
Closed -$332K – 2523
2019
Q1 		$332K Buy
+17,426
New +$227K ﹤0.01% 1672

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors's VYGR Position: Q2 2019 in Review

HighTower Advisors sold out of Voyager Therapeutics (VYGR) in Q2 2019, closing a stake of 17,426 shares — an estimated $332K sold.

HighTower Advisors first reported a position in VYGR in Q1 2019 and held it in 1 quarter. The position peaked at $332K in Q1 2019. 125 funds tracked by Wall St. Rank hold VYGR as of Q2 2019.

  • HighTower Advisors reported no remaining Voyager Therapeutics position as of Q2 2019 after selling out during the quarter.
  • HighTower Advisors sold 17,426 Voyager Therapeutics shares in Q2 2019, an estimated $332K.
  • HighTower Advisors first reported a position in Voyager Therapeutics in Q1 2019 and held it in 1 quarter.
  • HighTower Advisors's Voyager Therapeutics position peaked at $332K in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2019.

Based on HighTower Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.